{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:36:40Z","timestamp":1791351400924,"version":"4.3.1"},"reference-count":154,"publisher":"JLE","issue":"4","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.nephro.2016.05.005","type":"journal-article","created":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T20:47:44Z","timestamp":1467060464000},"page":"238-254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Glom\u00e9rulon\u00e9phrite \u00e0 d\u00e9p\u00f4ts m\u00e9sangiaux d\u2019immunoglobulines A"],"prefix":"10.1684","volume":"12","author":[{"given":"Evang\u00e9line","family":"Pillebout","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"V\u00e9rine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2016.05.005_bib0005","first-page":"939","article-title":"IgA glomerular deposits in renal disease","volume":"1","author":"Berger","year":"1969","journal-title":"Transplant Proc"},{"key":"10.1016\/j.nephro.2016.05.005_bib0010","first-page":"537","article-title":"IgA nephropathies","volume":"1","author":"Schena","year":"1998","journal-title":"Oxford Textbook Clin Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0015","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMra020109","article-title":"IgA nephropathy","volume":"347","author":"Donadio","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2016.05.005_bib0020","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000409761","article-title":"IgA nephropathy in chronic liver disease","volume":"40","author":"Nochy","year":"1984","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0025","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.semnephrol.2004.01.001","article-title":"Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome","volume":"24","author":"D\u2019Amico","year":"2004","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0030","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ki.2009.427","article-title":"IgA nephropathy at two score and one","volume":"77","author":"Coppo","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0035","first-page":"239","article-title":"The New Zealand Glomerulonephritis Study: introductory report","volume":"31","author":"Anon","year":"1989","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1445-5994.1987.tb05045.x","article-title":"Familial IgA nephropathy: a study of renal disease in an Australian aboriginal family","volume":"17","author":"O\u2019Connell","year":"1987","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.nephro.2016.05.005_bib0045","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0272-6386(12)80394-5","article-title":"Mesangial proliferative glomerulonephritis in southwestern American Indians","volume":"21","author":"Hoy","year":"1993","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2016.05.005_bib0050","first-page":"1879","article-title":"Incidence annuelle de la n\u00e9phropathie \u00e0 IgA (maladie de Berger) et du purpura d\u2019Henoch-Sch\u00f6nlein dans l\u2019est de la France","volume":"23","author":"Frimat","year":"1994","journal-title":"Presse Med"},{"key":"10.1016\/j.nephro.2016.05.005_bib0055","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1681\/ASN.V95853","article-title":"Epidemiology of IgA nephropathy in central and eastern Kentucky for the period 1975\u00a0through 1994. Central Kentucky Region of the Southeastern United States IgA Nephropathy DATABANK Project","volume":"9","author":"Wyatt","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0060","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1523-1755.2004.00834.x","article-title":"Epidemiologic data of primary glomerular diseases in western France","volume":"66","author":"Simon","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0065","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/ndt\/16.7.1364","article-title":"The incidence of biopsy-proven glomerulonephritis in Australia","volume":"16","author":"Briganti","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0070","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/sj.ki.5000292","article-title":"Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA?","volume":"69","author":"Nair","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0075","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/ndt\/gfg207","article-title":"A tricontinental view of IgA nephropathy","volume":"18","author":"Geddes","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0080","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/ki.1985.222","article-title":"Low incidence of IgA nephropathy in blacks","volume":"28","author":"Jennette","year":"1985","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0085","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000422395","article-title":"Multiplex families in IgA nephropathy","volume":"104","author":"Levy","year":"1993","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0090","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/81677","article-title":"IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23","volume":"26","author":"Gharavi","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.nephro.2016.05.005_bib0095","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2369-6-14","article-title":"The IgA nephropathy Biobank. An important starting point for the genetic dissection of a complex trait","volume":"6","author":"Schena","year":"2005","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0100","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1681\/ASN.2007020241","article-title":"Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36","volume":"18","author":"Paterson","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0105","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1086\/510135","article-title":"Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci","volume":"79","author":"Bisceglia","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nephro.2016.05.005_bib0110","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/ki.2011.16","article-title":"Aberrant glycosylation of IgA1\u00a0is inherited in both pediatric IgA nephropathy and Henoch-Schonlein purpura nephritis","volume":"80","author":"Kiryluk","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0115","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/ki.2015.252","article-title":"New developments in the genetics, pathogenesis, and therapy of IgA nephropathy","volume":"88","author":"Magistroni","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0120","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1056\/NEJM197805042981825","article-title":"HLA-Bw35\u00a0and mesangial IgA glomerulonephritis","volume":"298","author":"Berthoux","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2016.05.005_bib0125","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/ndt\/gfg010","article-title":"Polymorphisms of the tumour necrosis factor alpha gene at position -308\u00a0and TNFd microsatellite in primary IgA nephropathy","volume":"18","author":"Tuglular","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0130","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1053\/ajkd.2003.50046","article-title":"Impact of interferon-gamma and interleukin-4\u00a0gene polymorphisms on development and progression of IgA nephropathy in Japanese patients","volume":"41","author":"Masutani","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2016.05.005_bib0135","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/ndt\/17.4.542","article-title":"Controversies concerning the importance of genetic polymorphism in IgA nephropathy","volume":"17","author":"Frimat","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0140","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(95)91088-3","article-title":"Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy","volume":"345","author":"Harden","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2016.05.005_bib0145","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/jmg.40.2.104","article-title":"Association of the CD14\u00a0gene -159C polymorphism with progression of IgA nephropathy","volume":"40","author":"Yoon","year":"2003","journal-title":"J Med Genet"},{"key":"10.1016\/j.nephro.2016.05.005_bib0150","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1681\/ASN.2007121311","article-title":"Toll-like receptor\u00a09\u00a0affects severity of IgA nephropathy","volume":"19","author":"Suzuki","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0155","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/ndt\/gfp152","article-title":"Patients with IgA nephropathy exhibit high systemic PDGF-DD levels","volume":"24","author":"Boor","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0160","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1681\/ASN.2010010076","article-title":"HLA has strongest association with IgA nephropathy in genome-wide analysis","volume":"21","author":"Feehally","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0165","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ng.787","article-title":"Genome-wide association study identifies susceptibility loci for IgA nephropathy","volume":"43","author":"Gharavi","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.nephro.2016.05.005_bib0170","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/ndt\/14.8.1875","article-title":"IgA-gliadin antibodies, IgA-containing circulating immune complexes, and IgA glomerular deposits in wasting marmoset syndrome","volume":"14","author":"Schroeder","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0175","first-page":"463","article-title":"IgA nephropathy: lessons from an animal model, the ddY mouse","volume":"21","author":"Tomino","year":"2008","journal-title":"J Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0180","first-page":"1233","article-title":"Pathog\u00e9nie de la maladie de Berger: implication des immunoglobulines\u00a0A et de leurs r\u00e9cepteurs","volume":"19","author":"Monteiro","year":"2003","journal-title":"Med Sci"},{"key":"10.1016\/j.nephro.2016.05.005_bib0185","series-title":"Fundamental Immunology","author":"Paul","year":"1999"},{"key":"10.1016\/j.nephro.2016.05.005_bib0190","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/ki.1975.35","article-title":"Recurrence of mesangial deposition of IgA after renal transplantation","volume":"7","author":"Berger","year":"1975","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0195","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1046\/j.1523-1755.2001.00006.x","article-title":"Kidney transplantation in patients with IgA mesangial glomerulonephritis","volume":"60","author":"Ponticelli","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0200","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1399-0012.2004.00206.x","article-title":"The fate of glomerular mesangial IgA deposition in the donated kidney after allograft transplantation","volume":"18","author":"Ji","year":"2004","journal-title":"Clin Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0205","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/ki.1985.181","article-title":"Charge and size of mesangial IgA in IgA nephropathy","volume":"28","author":"Monteiro","year":"1985","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0210","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000422400","article-title":"The complement system in IgA nephropathy and Henoch-Schonlein purpura: functional and genetic aspects","volume":"104","author":"Wyatt","year":"1993","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0215","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1159\/000186474","article-title":"Confirmation of tonsillar anomalies in IgA nephropathy: a multicenter study","volume":"58","author":"Bene","year":"1991","journal-title":"Nephron"},{"key":"10.1016\/j.nephro.2016.05.005_bib0220","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/ki.1996.396","article-title":"Deficient IgA1\u00a0immune response to nasal cholera toxin subunit\u00a0B in primary IgA nephropathy","volume":"50","author":"de Fijter","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0225","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1067\/mlc.2002.129338","article-title":"Size-dependent binding of IgA to HepG2, U937, and human mesangial cells","volume":"140","author":"Leung","year":"2002","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.nephro.2016.05.005_bib0230","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/ndt\/16.9.1783","article-title":"Th2\u00a0predominance at the single-cell level in patients with IgA nephropathy","volume":"16","author":"Ebihara","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0235","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1471-4914(02)02405-X","article-title":"Pathogenic significance of IgA receptor interactions in IgA nephropathy","volume":"8","author":"Monteiro","year":"2002","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.nephro.2016.05.005_bib0240","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1046\/j.1523-1755.2001.060003969.x","article-title":"Mesangial IgA1\u00a0in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients","volume":"60","author":"Allen","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0245","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/ndt\/12.4.701","article-title":"Leucocyte beta 1,3\u00a0galactosyltransferase activity in IgA nephropathy","volume":"12","author":"Allen","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0250","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1093\/ndt\/gfp441","article-title":"Immune complex formation in IgA nephropathy: a case of the \u201cright\u201d antibodies in the \u201cwrong\u201d place at the \u201cwrong\u201d time?","volume":"24","author":"Barratt","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0255","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1023\/A:1012284402054","article-title":"Progress in molecular and genetic studies of IgA nephropathy","volume":"21","author":"Novak","year":"2001","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0260","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.semnephrol.2007.10.009","article-title":"IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy","volume":"28","author":"Novak","year":"2008","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0265","first-page":"1668","article-title":"Aberrantly glycosylated IgA1\u00a0in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity","volume":"119","author":"Suzuki","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nephro.2016.05.005_bib0270","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev.immunol.21.120601.141011","article-title":"IgA Fc receptors","volume":"21","author":"Monteiro","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0275","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/01.ASN.0000046961.04917.83","article-title":"Enhanced expression of the CD71\u00a0mesangial IgA1\u00a0receptor in Berger disease and Henoch-Schonlein nephritis: association between CD71\u00a0expression and IgA deposits","volume":"14","author":"Haddad","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0280","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.molmed.2015.10.003","article-title":"Molecular Insights into the Pathogenesis of IgA Nephropathy","volume":"21","author":"Robert","year":"2015","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.nephro.2016.05.005_bib0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10875-009-9338-0","article-title":"Role of IgA and IgA fc receptors in inflammation","volume":"30","author":"Monteiro","year":"2009","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0290","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/ki.2010.365","article-title":"Immune complex formation in IgA nephropathy: CD89\u00a0a \u201csaint\u201d or a \u201csinner\u201d?","volume":"78","author":"Boyd","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0295","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40620-015-0246-5","article-title":"Role of IgA receptors in the pathogenesis of IgA nephropathy","volume":"29","author":"Lechner","year":"2016","journal-title":"J Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0300","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/ndt\/gfg108","article-title":"Tonsillar IgA1\u00a0as a possible source of hypoglycosylated IgA1\u00a0in the serum of IgA nephropathy patients","volume":"18","author":"Itoh","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0305","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1093\/ndt\/gfq325","article-title":"Down-regulation of core 1\u00a0beta1,3-galactosyltransferase and Cosmc by Th2\u00a0cytokine alters O-glycosylation of IgA1","volume":"25","author":"Yamada","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0310","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2249.2009.04045.x","article-title":"Toll-like receptor 4\u00a0expression is increased in circulating mononuclear cells of patients with immunoglobulin A nephropathy","volume":"159","author":"Coppo","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0315","doi-asserted-by":"crossref","first-page":"221","DOI":"10.33549\/physiolres.930932","article-title":"Intrarenal gene expression of proinflammatory chemokines and cytokines in chronic proteinuric glomerulopathies","volume":"56","author":"Brabcova","year":"2007","journal-title":"Physiol Res"},{"key":"10.1016\/j.nephro.2016.05.005_bib0320","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1159\/000065465","article-title":"Prognostic value of urinary interleukin\u00a06\u00a0in patients with IgA nephropathy: an 8-year follow-up study","volume":"92","author":"Harada","year":"2002","journal-title":"Nephron"},{"key":"10.1016\/j.nephro.2016.05.005_bib0325","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1681\/ASN.2005020134","article-title":"IgA nephropathy","volume":"16","author":"Barratt","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0330","series-title":"Biopsie r\u00e9nale","author":"Droz","year":"1995"},{"key":"10.1016\/j.nephro.2016.05.005_bib0335","series-title":"Atlas de pathologie r\u00e9nale","author":"No\u00ebl","year":"2008"},{"key":"10.1016\/j.nephro.2016.05.005_bib0340","first-page":"676","article-title":"Histology and immunohistology of IgA nephropathy","volume":"18","author":"Haas","year":"2005","journal-title":"J Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0345","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/ki.2010.466","article-title":"Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. I. Immunohistochemical studies","volume":"79","author":"Hill","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0350","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2010111130","article-title":"A clinical study of thrombotic microangiopathy in IgA nephropathy","volume":"23","author":"El Karoui","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0355","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0272-6386(12)80284-8","article-title":"Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses","volume":"18","author":"Alamartine","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2016.05.005_bib0360","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000188848","article-title":"Steroid therapy during the early stage of progressive IgAN. A 10-year follow-up study","volume":"72","author":"Kobayashi","year":"1996","journal-title":"Nephron"},{"key":"10.1016\/j.nephro.2016.05.005_bib0365","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1681\/ASN.V82199","article-title":"Predicting renal outcome in IgA nephropathy","volume":"8","author":"Radford","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0370","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0046-8177(82)80221-9","article-title":"IgA nephropathy: morphologic predictors of progressive renal disease","volume":"13","author":"Lee","year":"1982","journal-title":"Hum Pathol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0375","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0272-6386(97)90456-X","article-title":"Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244\u00a0cases","volume":"29","author":"Haas","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2016.05.005_bib0380","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification","volume":"76","author":"Cattran","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0385","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/ki.2009.206","article-title":"A novel classification for IgA nephropathy","volume":"76","author":"Yamamoto","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0390","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ki.2009.168","article-title":"The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility","volume":"76","author":"Roberts","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0395","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00005792-199403000-00002","article-title":"IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literature","volume":"73","author":"Ibels","year":"1994","journal-title":"Medicine"},{"key":"10.1016\/j.nephro.2016.05.005_bib0400","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/ajkd.2000.8966","article-title":"Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors","volume":"36","author":"D\u2019Amico","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2016.05.005_bib0405","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/ki.2010.460","article-title":"Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies","volume":"79","author":"El Karoui","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0410","first-page":"363","article-title":"Prognostic indicators in idiopathic IgA mesangial N","volume":"59","author":"D\u2019Amico","year":"1986","journal-title":"Q J Med"},{"key":"10.1016\/j.nephro.2016.05.005_bib0415","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000168068","article-title":"IgA nephritis: on the importance of morphological and clinical parameters in the long-term prognosis of 239\u00a0patients","volume":"10","author":"Bogenschutz","year":"1990","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0420","first-page":"191","article-title":"An important role of glomerular segmental lesions on progression of IgA nephropathy: a multivariate analysis","volume":"41","author":"Katafuchi","year":"1994","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0425","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2169\/internalmedicine.40.697","article-title":"Heterogeneity of prognosis in adult IgA nephropathy, especially with mild proteinuria or mild histological features","volume":"40","author":"Usui","year":"2001","journal-title":"Intern Med"},{"key":"10.1016\/j.nephro.2016.05.005_bib0430","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0002-9343(01)00659-3","article-title":"The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria","volume":"110","author":"Szeto","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.nephro.2016.05.005_bib0435","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1681\/ASN.V11112062","article-title":"Polymorphism of angiotensin converting enzyme, angiotensinogen, and angiotensin\u00a0II type\u00a01\u00a0receptor genes and end-stage renal failure in IgA nephropathy: IGARAS--a study of 274\u00a0men","volume":"11","author":"Frimat","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000083224","article-title":"Tissue-specific expression of renin-angiotensin system components in IgA nephropathy","volume":"25","author":"Miyake-Ogawa","year":"2005","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0445","first-page":"503","article-title":"Factors predicting progression of IgA nephropathies","volume":"18","author":"Coppo","year":"2005","journal-title":"J Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0450","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1093\/ndt\/gfq768","article-title":"Polymorphisms in the nonmuscle myosin heavy chain 9\u00a0gene (MYH9) are associated with the progression of IgA nephropathy in Chinese","volume":"26","author":"Cheng","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0455","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/ki.2010.314","article-title":"Association of soluble CD89\u00a0levels with disease progression but not susceptibility in IgA nephropathy","volume":"78","author":"Vuong","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0460","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1093\/ndt\/gfr135","article-title":"High urinary excretion of kidney injury molecule-1\u00a0is an independent predictor of end-stage renal disease in patients with IgA nephropathy","volume":"26","author":"Peters","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0465","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ki.2008.66","article-title":"GMP-17-positive T-lymphocytes in renal tubules predict progression in early stages of IgA nephropathy","volume":"73","author":"van Es","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0470","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1093\/ndt\/gfn240","article-title":"Prediction of corticosteroid responsiveness based on fibroblast-specific protein 1 (FSP1) in patients with IgA nephropathy","volume":"23","author":"Harada","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0475","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/ndt\/gfn563","article-title":"Mesangial C4d deposition: a new prognostic factor in IgA nephropathy","volume":"24","author":"Espinosa","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0480","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1093\/ndt\/gfq812","article-title":"Immunostaining findings in IgA nephropathy: correlation with histology and clinical outcome in the Oxford classification patient cohort","volume":"26","author":"Bellur","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0485","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2215\/CJN.06720810","article-title":"Posttransplant recurrence of primary glomerulonephritis","volume":"5","author":"Ponticelli","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0490","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0272-6386(96)90137-7","article-title":"Recurrence of immunoglobulin\u00a0A nephropathy after renal transplantation in the cyclosporine era","volume":"28","author":"Kessler","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2016.05.005_bib0495","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1056\/NEJMoa013036","article-title":"Risk of renal allograft loss from recurrent glomerulonephritis","volume":"347","author":"Briganti","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2016.05.005_bib0500","first-page":"283","article-title":"Recurrent glomerulonephritis in the renal allograft: an update of selected areas","volume":"3","author":"Couser","year":"2005","journal-title":"Exp Clin Transplant"},{"issue":"Suppl.\u00a014","key":"10.1016\/j.nephro.2016.05.005_bib0505","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1399-0012.2005.00403.x","article-title":"Latent IgA deposition from donor kidney is the major risk factor for recurrent IgA nephropathy in renal transplantation","volume":"19","author":"Moriyama","year":"2005","journal-title":"Clin Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0510","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/ndt\/gfh773","article-title":"Recurrent IgA nephropathy after renal transplantation despite immunosuppressive regimens with mycophenolate mofetil","volume":"20","author":"Chandrakantan","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0515","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1053\/j.ajkd.2010.03.033","article-title":"Pregnancy and progression of IgA nephropathy: results of an Italian multicenter study","volume":"56","author":"Limardo","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2016.05.005_bib0520","first-page":"31","article-title":"IgA nephropathy and pregnancy","volume":"23","author":"Koido","year":"1998","journal-title":"Tokai J Exp Clin Med"},{"key":"10.1016\/j.nephro.2016.05.005_bib0525","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1038\/sj.ki.5000434","article-title":"The IgA nephropathy treatment dilemma","volume":"69","author":"Appel","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0530","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1038\/sj.ki.5000419","article-title":"Treatment of IgA N","volume":"69","author":"Barratt","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0535","first-page":"354","article-title":"Present and future therapy options in IgA-nephropathy","volume":"18","author":"Floege","year":"2005","journal-title":"J Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0540","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1053\/j.ajkd.2011.05.033","article-title":"The pathogenesis of IgA nephropathy: what is new and how does it change therapeutic approaches?","volume":"58","author":"Floege","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2016.05.005_bib0545","first-page":"139","article-title":"KDIGO Clinical Practice Guideline for Glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0550","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.nephro.2016.05.005_bib0555","first-page":"CD003962","article-title":"Non-immunosuppressive treatment for IgA nephropathy","author":"Reid","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nephro.2016.05.005_bib0560","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/ndt\/gfh920","article-title":"Renal protection in IgA nephropathy requires strict blood pressure control","volume":"20","author":"Nagy","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0565","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","article-title":"Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial","volume":"14","author":"Praga","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0570","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/qjmed\/hci036","article-title":"Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation","volume":"98","author":"Kanno","year":"2005","journal-title":"QJM"},{"key":"10.1016\/j.nephro.2016.05.005_bib0575","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1681\/ASN.2006040347","article-title":"IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria","volume":"18","author":"Coppo","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0580","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/ndt\/gfg090","article-title":"Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1\u00a0in patients with IgA nephropathy","volume":"18","author":"Park","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0585","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","article-title":"Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study","volume":"47","author":"Li","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2016.05.005_bib0590","doi-asserted-by":"crossref","first-page":"617","DOI":"10.5414\/CNP71617","article-title":"Beneficial effects of high-dose losartan in IgA nephritis","volume":"71","author":"Woo","year":"2009","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0595","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.1742-1241.2009.02038.x","article-title":"ACEI\/ARB therapy for IgA N: a meta analysis of randomised controlled trials","volume":"63","author":"Cheng","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.nephro.2016.05.005_bib0600","doi-asserted-by":"crossref","first-page":"e62736","DOI":"10.1371\/journal.pone.0062736","article-title":"The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy--a randomized cross-over study","volume":"8","author":"Szeto","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.nephro.2016.05.005_bib0605","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1440-1797.2004.00255.x","article-title":"Immunosuppressive treatments for immunoglobulin\u00a0A nephropathy: a meta-analysis of randomized controlled trials","volume":"9","author":"Samuels","year":"2004","journal-title":"Nephrology"},{"key":"10.1016\/j.nephro.2016.05.005_bib0610","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000226129","article-title":"Efficacy and safety of glucocorticoids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials","volume":"30","author":"Cheng","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0615","doi-asserted-by":"crossref","first-page":"e18788","DOI":"10.1371\/journal.pone.0018788","article-title":"Steroids in the treatment of IgA nephropathy to the improvement of renal survival: a systematic review and meta-analysis","volume":"6","author":"Zhou","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.nephro.2016.05.005_bib0620","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrneph.2015.47","article-title":"Glomerular disease: Efficacy of corticosteroids in high-risk IgA nephropathy","volume":"11","author":"Floege","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0625","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","article-title":"Corticosteroids in IgA nephropathy: a randomised controlled trial","volume":"353","author":"Pozzi","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2016.05.005_bib0630","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","article-title":"Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial","volume":"15","author":"Pozzi","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0635","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0272-6386(03)00194-X","article-title":"Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy","volume":"41","author":"Katafuchi","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2016.05.005_bib0640","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1093\/ndt\/gfn394","article-title":"The improvement of renal survival with steroid pulse therapy in IgA nephropathy","volume":"23","author":"Katafuchi","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0645","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/ndt\/gfg135","article-title":"Steroid therapy reduces mesangial matrix accumulation in advanced IgA nephropathy","volume":"18","author":"Kuriki","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0650","first-page":"174","article-title":"Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial","volume":"26","author":"Lai","year":"1986","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0655","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","article-title":"Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial","volume":"53","author":"Lv","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2016.05.005_bib0660","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy","volume":"24","author":"Manno","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0665","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1681\/ASN.V131142","article-title":"Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy","volume":"13","author":"Ballardie","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0670","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1681\/ASN.2010010117","article-title":"Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy","volume":"21","author":"Pozzi","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0675","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10157-011-0415-3","article-title":"Steroids and azathioprine in the treatment of IgA nephropathy","volume":"15","author":"Stangou","year":"2011","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0680","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","article-title":"Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study","volume":"65","author":"Maes","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0685","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ki.2009.499","article-title":"Long-term study of mycophenolate mofetil treatment in IgA nephropathy","volume":"77","author":"Tang","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0690","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","article-title":"Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial","volume":"20","author":"Frisch","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0695","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1159\/000168483","article-title":"Mycophenolate mofetil treatment for IgA nephropathy: a meta-analysis","volume":"29","author":"Xu","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0700","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","article-title":"Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy","volume":"66","author":"Hogg","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2016.05.005_bib0705","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1046\/j.1523-1755.2000.00930.x","article-title":"Suppressive effects of fish oil on mesangial cell proliferation in vitro and in vivo","volume":"57","author":"Grande","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0710","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1056\/NEJM199411033311804","article-title":"A controlled trial of fish oil in IgA nephropathy","volume":"331","author":"Donadio","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2016.05.005_bib0715","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1681\/ASN.V124791","article-title":"A randomized trial of high-dose compared with low-dose omega-3\u00a0fatty acids in severe IgA nephropathy","volume":"12","author":"Donadio","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0720","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2215\/CJN.01020905","article-title":"Clinical trial to evaluate omega-3\u00a0fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group","volume":"1","author":"Hogg","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0725","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/ndt\/gfn454","article-title":"Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial","volume":"24","author":"Ferraro","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0730","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/03655230410003369","article-title":"Clinical involvement of the tonsillar immune system in IgA nephropathy","volume":"555","author":"Bene","year":"2004","journal-title":"Acta Otolaryngol (Suppl)"},{"key":"10.1016\/j.nephro.2016.05.005_bib0735","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1046\/j.1523-1755.2003.00935.x","article-title":"The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy","volume":"63","author":"Xie","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.05.005_bib0740","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/ajkd.2001.27690","article-title":"Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy","volume":"38","author":"Hotta","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2016.05.005_bib0745","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2215\/CJN.00310108","article-title":"Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study","volume":"3","author":"Komatsu","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0750","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/ndt\/gfq674","article-title":"A meta-analysis of the clinical remission rate and long-term efficacy of tonsillectomy in patients with IgA nephropathy","volume":"26","author":"Wang","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0755","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0272-6386(85)80134-7","article-title":"\u201cMalignant\u201d IgA nephropathy","volume":"5","author":"Nicholls","year":"1985","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2016.05.005_bib0760","first-page":"37","article-title":"Participation of extracapillary lesions (ECL) in progression of IgA nephropathy","volume":"25","author":"Abe","year":"1986","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2016.05.005_bib0765","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/ndt\/gfg081","article-title":"Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide","volume":"18","author":"Tumlin","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.05.005_bib0770","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1093\/ndt\/gfr052","article-title":"New treatment of IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria","volume":"26","author":"Smerud","year":"2011","journal-title":"Nephrol Dial Transplant"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725516300712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725516300712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2016.05.005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T13:42:37Z","timestamp":1741182157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725516300712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":154,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1769725516300712"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2016.05.005","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glom\u00e9rulon\u00e9phrite \u00e0 d\u00e9p\u00f4ts m\u00e9sangiaux d\u2019immunoglobulines A","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2016.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Association Soci\u00e9t\u00e9 de n\u00e9phrologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}